Effect of EECP on Anterior Ischemic Optic Neuropathy (AION)
This study is currently recruiting participants.
Verified January 2013 by First Affiliated Hospital, Sun Yat-Sen University
Sponsor:
First Affiliated Hospital, Sun Yat-Sen University
Information provided by (Responsible Party):
WenHui Zhu, First Affiliated Hospital, Sun Yat-Sen University
ClinicalTrials.gov Identifier:
NCT01768260
First received: January 8, 2013
Last updated: January 11, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Enhanced External Counterpulsation(EECP) therapy may promote the recovery of visual function by improving the blood perfusion of eyes. The present study aims to investigate the effect of EECP on Anterior Ischemic Optic Neuropathy.
| Condition | Intervention |
|---|---|
|
Anterior Ischemic Optic Neuropathy |
Device: Enhanced external counterpulsation Drug: Aspirin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Study of the Effect of EECP on Anterior Ischemic Optic Neuropathy |
Resource links provided by NLM:
Genetics Home Reference related topics:
Charcot-Marie-Tooth disease
hereditary neuropathy with liability to pressure palsies
Drug Information available for:
Aspirin
U.S. FDA Resources
Further study details as provided by First Affiliated Hospital, Sun Yat-Sen University:
Primary Outcome Measures:
- visual acuity [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Ophthalmic artery blood flow velocity [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]
Other Outcome Measures:
- Central retinal artery flow velocity [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | December 2012 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Enhanced External conterpulsation
Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.
|
Device: Enhanced external counterpulsation
EECP is performed for 1 hours every day, for a total of 36 hours.
Other Name: EECP
Drug: Aspirin
Standard drug therapy
Other Name: aspirin
|
|
Active Comparator: aspirin
The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy.
|
Drug: Aspirin
Standard drug therapy
Other Name: aspirin
|
Detailed Description:
Patients with Anterior Ischemic Optic Neuropathy are randomized into two groups: one group receive standard medical treatment for ischemic optic neuropathy, the other group plus EECP therapy besides standard medical treatment.
Eligibility| Ages Eligible for Study: | 40 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- ischemic optic neuropathy
- within 1 month
Exclusion Criteria:
- Hemorrhagic disease
- thrombophlebitis or infection lesions
- severe hypertensive patients
- Atrial fibrillation
- Aortic regurgitation
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01768260
Contacts
| Contact: Yan Zhang, MD | 862087755766 ext 8141 | Zhyan3@mail.sysu.edu.cn |
Locations
| China, Guangdong | |
| The First Affiliated Hospital of Sun Yat- sen University | Recruiting |
| Guangzhou, Guangdong, China, 510080 | |
| Contact: Ling Zhang, MA 862087755766 ext 8035 Zhanglingaben@126.com | |
Sponsors and Collaborators
First Affiliated Hospital, Sun Yat-Sen University
Investigators
| Study Director: | Yan Zhang, Professor | First Affiliated Hospital of Sun Yat-sen University |
More Information
Publications:
| Responsible Party: | WenHui Zhu, Oculist-in-charge, First Affiliated Hospital, Sun Yat-Sen University |
| ClinicalTrials.gov Identifier: | NCT01768260 History of Changes |
| Other Study ID Numbers: | Eye EECP-1 |
| Study First Received: | January 8, 2013 |
| Last Updated: | January 11, 2013 |
| Health Authority: | China: National Natural Science Foundation |
Keywords provided by First Affiliated Hospital, Sun Yat-Sen University:
|
visual acuity artery flow velocity Enhanced External Counterpulsation Ischemic Optic Neuropathy |
Additional relevant MeSH terms:
|
Ischemia Optic Nerve Diseases Optic Neuropathy, Ischemic Demyelinating Diseases Polyneuropathies Nerve Compression Syndromes Neurologic Manifestations Neurotoxicity Syndromes Pathologic Processes Cranial Nerve Diseases Nervous System Diseases Eye Diseases Vascular Diseases Cardiovascular Diseases Peripheral Nervous System Diseases |
Neuromuscular Diseases Signs and Symptoms Poisoning Substance-Related Disorders Aspirin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents |
ClinicalTrials.gov processed this record on May 23, 2013